vs
Side-by-side financial comparison of Pangaea Logistics Solutions Ltd. (PANL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pangaea Logistics Solutions Ltd. is the larger business by last-quarter revenue ($183.9M vs $177.4M, roughly 1.0× Pacira BioSciences, Inc.). Pangaea Logistics Solutions Ltd. runs the higher net margin — 6.5% vs 1.6%, a 4.8% gap on every dollar of revenue. On growth, Pangaea Logistics Solutions Ltd. posted the faster year-over-year revenue change (24.9% vs 5.0%). Over the past eight quarters, Pangaea Logistics Solutions Ltd.'s revenue compounded faster (32.5% CAGR vs -0.2%).
Pangaea Logistics Solutions Ltd. is a global dry bulk logistics and shipping service provider. It operates a modern fleet of dry bulk vessels to transport a wide range of commodities including grains, minerals, construction materials, and energy-related raw materials, serving industrial, agricultural, and energy sector clients across North America, Europe, and Asia with tailored end-to-end bulk cargo supply chain solutions.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PANL vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.9M | $177.4M |
| Net Profit | $11.9M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 9.5% | 3.9% |
| Net Margin | 6.5% | 1.6% |
| Revenue YoY | 24.9% | 5.0% |
| Net Profit YoY | 40.9% | — |
| EPS (diluted) | $0.18 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $183.9M | $196.9M | ||
| Q3 25 | $168.7M | $179.5M | ||
| Q2 25 | $156.7M | $181.1M | ||
| Q1 25 | $122.8M | $168.9M | ||
| Q4 24 | $147.2M | $187.3M | ||
| Q3 24 | $153.1M | $168.6M | ||
| Q2 24 | $131.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $11.9M | — | ||
| Q3 25 | $12.2M | $5.4M | ||
| Q2 25 | $-2.7M | $-4.8M | ||
| Q1 25 | $-2.0M | $4.8M | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $5.1M | $-143.5M | ||
| Q2 24 | $3.7M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 9.5% | 1.2% | ||
| Q3 25 | 10.0% | 3.5% | ||
| Q2 25 | 2.3% | 4.7% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 10.1% | 13.2% | ||
| Q3 24 | 9.8% | -82.8% | ||
| Q2 24 | 5.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 6.5% | — | ||
| Q3 25 | 7.2% | 3.0% | ||
| Q2 25 | -1.8% | -2.7% | ||
| Q1 25 | -1.6% | 2.8% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.3% | -85.1% | ||
| Q2 24 | 2.8% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.18 | $0.05 | ||
| Q3 25 | $0.19 | $0.12 | ||
| Q2 25 | $-0.04 | $-0.11 | ||
| Q1 25 | $-0.03 | $0.10 | ||
| Q4 24 | $0.19 | $0.38 | ||
| Q3 24 | $0.11 | $-3.11 | ||
| Q2 24 | $0.08 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.1M | $144.3M |
| Total DebtLower is stronger | $249.6M | — |
| Stockholders' EquityBook value | $429.3M | $653.9M |
| Total Assets | $928.1M | $1.2B |
| Debt / EquityLower = less leverage | 0.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $103.1M | $238.4M | ||
| Q3 25 | $94.0M | $246.3M | ||
| Q2 25 | $59.3M | $445.9M | ||
| Q1 25 | $63.9M | $493.6M | ||
| Q4 24 | $86.8M | $484.6M | ||
| Q3 24 | $93.1M | $453.8M | ||
| Q2 24 | $77.9M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $249.6M | $372.2M | ||
| Q3 25 | $256.2M | $376.7M | ||
| Q2 25 | $244.7M | $580.5M | ||
| Q1 25 | $251.0M | $583.4M | ||
| Q4 24 | $257.2M | $585.3M | ||
| Q3 24 | $133.6M | — | ||
| Q2 24 | $90.5M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $429.3M | $693.1M | ||
| Q3 25 | $420.3M | $727.2M | ||
| Q2 25 | $414.4M | $757.8M | ||
| Q1 25 | $420.8M | $798.5M | ||
| Q4 24 | $427.8M | $778.3M | ||
| Q3 24 | $332.6M | $749.6M | ||
| Q2 24 | $331.5M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $928.1M | $1.3B | ||
| Q3 25 | $932.1M | $1.3B | ||
| Q2 25 | $916.0M | $1.5B | ||
| Q1 25 | $918.0M | $1.6B | ||
| Q4 24 | $936.5M | $1.6B | ||
| Q3 24 | $749.2M | $1.5B | ||
| Q2 24 | $692.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.58× | 0.54× | ||
| Q3 25 | 0.61× | 0.52× | ||
| Q2 25 | 0.59× | 0.77× | ||
| Q1 25 | 0.60× | 0.73× | ||
| Q4 24 | 0.60× | 0.75× | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.27× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.1M | $43.7M | ||
| Q3 25 | $28.6M | $60.8M | ||
| Q2 25 | $14.4M | $12.0M | ||
| Q1 25 | $-4.4M | $35.5M | ||
| Q4 24 | $19.3M | $33.1M | ||
| Q3 24 | $28.5M | $53.9M | ||
| Q2 24 | $9.0M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 1.27× | — | ||
| Q3 25 | 2.34× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 5.57× | — | ||
| Q2 24 | 2.43× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PANL
| Voyage | $166.3M | 90% |
| Charter | $13.1M | 7% |
| Terminal Stevedore Revenue | $4.4M | 2% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
